GENinCode UK Ltd. (GB:GENI) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
GENinCode UK Ltd. has published a study highlighting the impact of lifestyle and genetic factors on coronary heart disease, showcasing that individuals with high polygenic risk can significantly reduce their risk through lifestyle changes. The company’s CARDIO inCode-Score® is gaining adoption in leading U.S. healthcare institutions, contributing to its projected revenue growth of up to 39% for 2024. GENinCode continues to expand its market presence, marking its first U.S. revenues and strengthening its position in the cardiovascular disease prevention sector.
For further insights into GB:GENI stock, check out TipRanks’ Stock Analysis page.